Protection against Transfusion-Associated Graft-versus-Host Disease in Blood Transfusion: Is Gamma-Irradiation the only Answer?

Transfusion Medicine and Hemotherapy

Volumn 31, Issue SUPPL. 1, 2004, Pages 24-31

  Schlenke, P ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Graft versus host disease; Irradiation; Pathogen inactivation; Transfusion

Indexed keywords

AMOTOSALEN; CD69 ANTIGEN; CELL NUCLEUS DNA; CESIUM 137; COBALT 60; CYTOKINE; DOUBLE STRANDED DNA; FRESH FROZEN PLASMA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN; PSORALEN DERIVATIVE; SINGLE STRANDED DNA; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIGEN EXPRESSION; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; BACTERIAL GENOME; BACTERIUM CONTAMINATION; BLOOD COMPONENT; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CELL DIVISION; CLINICAL FEATURE; CYTOKINE PRODUCTION; DNA DAMAGE; DNA MODIFICATION; DNA REPLICATION; DNA STRAND BREAKAGE; DOSIMETER; DOSIMETRY; ERYTHROCYTE TRANSFUSION; FATALITY; FREEZING; GAMMA IRRADIATION; GENE REPLICATION; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; LEUKOCYTE FUNCTION; LYMPHOCYTE FUNCTION; PARASITE; PATHOGENESIS; PLASMA TRANSFUSION; PROPHYLAXIS; RADIATION DOSE; RADIATION EQUIPMENT; REVIEW; RISK REDUCTION; SAFETY; SKIN BIOPSY; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTE TRANSFUSION; ULTRAVIOLET A RADIATION; VIRAL CONTAMINATION; VIRUS GENOME; VIRUS INACTIVATION;

EID: 1342344031     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076977     Document Type: Review

References (53)

1. Goodnough LT, Brecher ME, Kanter MH, et al: Transfusion Medicine. Review Part I and II. N Engl J Med 1999;340:438-447 and 525-533.
2. Goodnough LT, Shander A, Brecher ME: Transfusion Medicine: Looking to the future. Lancet 2003;361:161-169.
3. Luban NL: Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet components. Sem Hematol 2001;38(suppl 11):34-45.
4. Stowell CP, Levin J, Spiess BD, et al: Progress in the development of RBC substitutes. Transfusion 2001;41:287-299.
5. Van Rhenen D, Gulliksson H, Cazenave JP, et al: Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: euro-SPRITE trial. Blood 2003;101:2426-2433.
6. Wahr JA, Trouwborst A, Spence RK, et al: A pilot study of the effects of perflubron emulsion, AF0104, on mixed venous oxygen tension in anesthetized surgical patients. Anesth Analg 1996;82:103-107.
7. Teshima T, Ferrera JL: Understanding the alloresponse: New approaches to graft-versus-host disease prevention. Sem Hematol 2002;39:15-22.
8. Anderson KC, Weinstein HJ: Transfusion-associated graft-versus-host disease. N Engl J Med 1990;323:315-321.
9. Parkman R, Mosier D, Umansky I, et al: Graft-vs-host disease after intrauterine and exchange transfusions for hemolytic disease of the newborn. N Engl J Med 1974;290:359-363.
10. Briz M, Cabrera R, Sanjuan I, et al: Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukemia. Br J Haematol 1995;91:409-411.
11. Williamson LM, Wimperis JZ, Wood ME, et al: Fludarabine treatment and transfusion-associated graft-versus-host disease. Lancet 1996;348: 472-473.
12. Gelly KJ, Kerr R, Rawlinson S: Transfusion-associated graft vs. host disease in a patient with high-grade B-cell lymphoma. Should cellular products for patients with non-Hodgkin's lymphoma be irradiated? Brit J Hematol 2000;110:228-229.
13. Triulzi DJ, Nalesnik MA: Microchimerism, GvHD, and tolerance in solid organ transplantation. Transfusion 2001;41:419-426.
14. SHOT (Serious Hazards of Transfusion) Annual Report 2000/2001 published by The Serious Hazards of Transfusion Steering Group. Available at: www.shot.demon.co.uk
15. Munro LR, Culligan DJ, Grant A, et al: Transfusion-associated graft-versus-host disease in a patient with Waldenstrom's macroglobulinaemia. Vox Sang 2002;83:279-281.
16. Hutchinson K, Kopko PM, Muto KN, et al: Early diagnosis and successful treatment of a patient with transfusion-associated GvHD with autologous peripheral blood progenitor cell transplantation. Transfusion 2002;42:1567-1572.
17. Klein C, Fraitag S, Foulon E: Moderate and transient transfusion- associated cutaneous graft versus host disease in a child infected by human immunodeficiency virus. Am J Med 1996;101:445-446.
18. Juji T, Takahashi K, Shibata Y, et al: Post-transfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan. N Engl J Med 1989;321:56.
19. Anderson KC, Goodnough LT, Sayers M, et al: Variation in blood component irradiation practice: Implications for prevention of transfusion-associated graft-vs.-host disease. Blood 1991;77:2096-2102.
20. Ohto H, Anderson KC: Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients. Transfus Med Rev 1996;10:31-43.
21. Müller-Steinhardt M, Hennig H, Kirchner H, et al: Prestorage WBC filtration of RBC units with soft-shell filters: Filtration performance and impact on RBCs during storage for 42 days. Transfusion 2002;42:153-158.
22. Pelszynski MM, Moroff G, Luban NL, et al: Effect of gamma irradiation on T-cell inactivation as assessed by limiting dilution analysis: Implications for preventing transfusion associated graft vs. host disease. Blood 1994;83:1683-1689.
23. Kunstmann E, Bocker T, Roewer L, et al: Diagnosis of transfusion- associated graft-versus-host disease by genetic fingerprinting and polymerase chain reaction. Transfusion 1992;32:766-770.
24. Wang L, Juji T, Tokunaga K, et al: Polymorphic microsatellite markers for the diagnosis of graft-versus-host disease. N Engl J Med 1994;330:398-401.
25. Lee TH, Donegan E, Slichter S, et al: Transient increase in circulating donor leukocytes after allogeneic transfusions in immunocompetent transfusion recipients compatible with donor cell proliferation. Blood 1996;85:1207-1214.
26. Wang-Rodriguez J, Fry E, Fiebig E, et al: Immune response to blood transfusion in very low birthweight infants. Transfusion 2000;40:25-34.
27. Vietor HE, Hallensleben E, van Bree SP, et al.: Survival of donor cells 25 years after intrauterine transfusion. Blood 2000;95:2709-2714.
28. McMilan KD, Johnson RL: HLA-homozygosity and the risk of related-donor transfusion-associated graft-versus-host disease. Transfus Med Rev 1993;7:37-41.
29. Thaler M, Shamiss A, Orgad S: The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med 1989;321:25-28.
30. Kruskall MS: The major histocompatibility complex: The values of extended haplotypes in the analysis of associated immune diseases and disorders. Yale J Biol Med 1990;63:477-486.
31. Wagner FF, Flegel WA: Transfusion-associated graft-versus-host disease: Risk due to homozygous HLA haplotypes. Transfusion 1995;35:284-291.
32. Ferrera JM, Krenger W: Graft-versus-host disease: The influence of type 1 and type 2 T-cell cytokines. Transfus Med Rev 1998;12:1-17.
33. Leitman SF: Use of blood cell irradiation in the prevention of post-transfusion graft-vs-host disease. Transfus Sci 1989;10:219-232.
34. Leitman SF: Dose, dosimetry and quality improvement of irradiated blood components. Transfusion 1993;33:447-449.
35. Linden JV, Pisciotto PT: Transfusion-associated graft-versus-host disease and blood irradiation. Transfus Med Rev 1992;6:116-123.
36. Shlomchik WD, Couzens MS, Tang CB, et al: Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412-415.
37. Gresens CJ, Paglieroni T, Moss CB, et al: T-cells in fresh frozen plasma are viable and can respond to mitogen, superantigen and allogeneic monocytes (abstract). Transfusion 1999;39:99S.
38. FDA: Recommendations regarding license amendments and procedures for gamma irradiation of blood products. Food and Drug Administration, 1993.
39. BCSH Blood Transfusion Task Force: Guidelines on gamma irradiation of blood components for the prevention of transfusion associated graft-versus-host disease. Transfus Med 1996;6:261-271.
40. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Aufgestellt vom Wissenschaftlichen Beirat der Bundesärztekammer und vom Paul-Ehrlich-Institut. Deutscher Ärzteverlag 2000/2001.
41. EC Guide to Good Manufacturing Practice for Medicinal Products including Annex 12: Use of Ionizing Radiation in the Manufacture of Medicinal Products. Commission of the European Communities, 1992.
42. Guide to the preparation, use and quality assurance of blood components, ed 8. Council of Europe Strasbourg: Council of Europe Publishing, 2002.
43. Davey RJ, McCoy NC, Yu M, et al: The effect of prestorage irradiation on post-transfusion red cell survival. Transfusion 1992;32:525-528.
44. Moroff G, George VM, Siegl M, et al: The influence of irradiation on stored platelets. Transfusion 1986;26:453-456.
45. Read EJ, Kodis C, Carter CS, et al: Viability of platelets following storage in the irradiated state. A pair-controlled study. Transfusion 1988;28:446-450.
46. Sweeney JD, Holme S, Moroff G: Storage of apheresis platelets after gamma irradiation. Transfusion 1994;34:779-783.
47. Zimmermann R, Schmidt S, Zingsem J, et al: Effect of gamma radiation on the in vitro aggregability of WBC-reduced apheresis platelets. Transfusion 2001;41:236-242.
48. Lin L, Cook DN, Wiesehahn GP, et al: Photochemical inactivation of viruses and bacteria in human platelet concentrates using a novel psoralen and long wavelength UV light. Transfusion 1997;37:423-435.
49. Wollowitz S: Fundamentals of the psoralen-based Helinx Technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Sem Hematol 2001;38:4-11.
50. Grass JA, Hei DJ, Metchette K, et al: Inactivation of leukocytes in platelet concentrates by psoralen plus UVA. Blood 1998;91:2180-2188.
51. Lowenthal RM, Challis DR, Griffiths AE: Transfusion-associated graft-versus-host disease: Report of an occurrence following the administration of irradiated blood. Transfusion 1993;33:524-529.
52. Hei DJ, Grass J, Lin L: Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999;39:239-248.
53. Grass JA, Wafa T, Reames A, et al: Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999;93:3140-3147.